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Background: Organizing pneumonia (OP), so called bronchiolitis obliterans organizing pneumonia after
postoperative irradiation for breast cancer has been often reported. There is little information about OP after other
radiation modalities. This cohort study investigated the clinical features and risk factors of OP after stereotactic
ablative radiotherapy of the lung (SABR).
Methods: Patients undergoing SABR between 2004 and 2010 in two institutions were investigated. Blood test and
chest computed tomography were performed at intervals of 1 to 3 months after SABR. The criteria for diagnosing
OP were: 1) mixture of patchy and ground-glass opacity, 2) general and/or respiratory symptoms lasting for at least
2 weeks, 3) radiographic lesion in the lung volume receiving < 0.5 Gy, and 4) no evidence of a specific cause.
Results: Among 189 patients (164 with stage I lung cancer and 25 with single lung metastasis) analyzed, nine
developed OP. The incidence at 2 years was 5.2% (95% confidence interval; 2.6-9.3%). Dyspnea were observed
in all patients. Four had fever. These symptoms and pulmonary infiltration rapidly improved after corticosteroid
therapy. Eight patients had presented with symptomatic radiation pneumonitis (RP) around the tumor 2 to
7 months before OP. The prior RP history was strongly associated with OP (hazard ratio 61.7; p= 0.0028) in
multivariate analysis.
Conclusions: This is the first report on OP after SABR. The incidence appeared to be relatively high. The symptoms
were sometimes severe, but corticosteroid therapy was effective. When patients after SABR present with unusual
pneumonia, OP should be considered as a differential diagnosis, especially in patients with prior symptomatic RP.
Keywords: Stereotactic ablative radiotherapy (SABR), Organizing pneumonia, Lung cancer, Radiation pneumonitisIntroduction
Organizing pneumonia (OP), so called bronchiolitis
obliterans organizing pneumonia, is a rare interstitial
lung disease having unique clinical, radiological and
pathological characteristics [1-3]. Typical OP patients
present with dyspnea, cough, and fever that have been
developing over a few weeks. Dramatic improvement is
achieved by corticosteroids, but relapses occur fre-
quently after corticosteroid therapy is tapered or
stopped. Since Crestani et al. [4]. reported OP after post-
operative irradiation for breast cancer in 1998, several
reports have described the features, which are different* Correspondence: taro8864@yahoo.co.jp
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reproduction in any medium, provided the orfrom those of radiation pneumonitis (RP) [5-10]. The
infiltrates initially appear in the irradiated side of the
lung and migrate outside the radiation field. These fea-
tures lead to the notion that radiation injury may prime
the development of OP. However, no reports have
demonstrated the relationship between radiation injury
and OP, and there is little information about OP after
other radiation modalities.
Stereotactic ablative radiotherapy of the lung (SABR),
previously called stereotactic body radiotherapy of the
lung is a technique to precisely deliver radiation to a tar-
geted tumor. Although surgical resection has been
regarded as standard therapy for early stage non-small
cell lung cancer (NSCLC) and solitary lung metastases,
recent reports on SABR for inoperable patients show
minimal morbidity and high local control rates [11-15].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or solitary lung metastasis treated with SABR have re-
cently increased for the reasons they are medically inop-
erable or refuse surgery [16].
To the best of our knowledge, OP after SABR has not
been reported yet. We herein describe the clinical fea-
tures of OP after SABR performed at two institutions.
The objective of this study was 1) to describe the inci-




Nearly all data used in this study were obtained from
patients enrolled in multi-institutional protocol-based
SABR studies [13,14,17-19]. Between April 2004 and
May 2010, 210 patients entered the SABR studies at two
institutions (Nagoya City University Hospital and Nagoya
Daini Red Cross Hospital). All these patients had
T1N0M0 or T2aN0M0 stage NSCLC according to the
7th edition of TNM staging at diagnosis, or single lung
metastasis. Local recurrences after surgery less than 5 cm
in diameter were included. The patients’ medical records,
radiotherapy documents and images were reviewed. Of
the 210 patients, seven had undergone prior chest irradi-
ation and 14 had interstitial lung disease diagnosed based
on clinical symptoms, Kerbs von Lungren (KL)-6 eleva-
tion, computed tomography (CT) findings and/or biopsy
[18]. These patients were excluded from analysis because
it is hard to distinguish RP after prior radiotherapy or ex-
acerbation of interstitial pneumonia from OP after SABR.
Thus, 189 patients were analyzed. The characteristics of
these patients are shown in Table 1. Four patients had a
previous diagnosis of rheumatoid arthritis. All patients
provided written informed consent. This study was
approved by the institutional research and ethics com-
mittees (Nagoya City University Hospital, No. 532 and
Nagoya Daini Red Cross Hospital, IRB20110125-1).
Treatment methods
Our methods for treatment planning were described in
detail previously [13,14]. The clinical target volume
(CTV) was defined as the visible gross tumor volume.
The CTV was expanded to the internal target volume
(ITV), considering respiratory motion of the CTV. The
ITV was extended by 5 to 10 mm to represent the plan-
ning target volume (PTV). Irradiation to the PTV was
delivered using three coplanar and four noncoplanar
static ports. SABR was delivered by a linear accelerator
with 6-megavolt photons.
Prescription dose
The prescribed dose was delivered to the isocenter de-
pending on the maximum diameter. On the protocols,the dose was 48 or 50 Gy in 4 fractions for both NSCLC
and metastasis with a longest diameter of 1.5 to 3 cm,
and 52 Gy in 4 fractions for tumors larger than 3 cm.
Smaller NSCLC (< 1.5 cm) were treated with 44 or
48 Gy in 4 fractions and smaller metastases (< 1.5 cm)
were irradiated at 34 or 36 Gy in 2 fractions. Beginning
in January 2009, concurrent chemotherapy with TS-1
(80 mg/m [2] per day) was administered to 4 patients
with T2a NSCLC over 28 days. Chemotherapy for other
cancers such as colorectal cancer and small cell lung
cancer was carried out in 3 patients during SABR.
All patients, except for two initial cases treated with
54 Gy in 6 fractions, were treated on this protocol
(Table 1). Most patients (175/189) received 48 to 52 Gy
in 4 fractions. The Eclipse AAA system or Pinnacle (3)
collapsed cone convolution were used as the dose calcu-
lation algorithm. Lung volume covered with 20 Gy or
more (V20 Gy), mean lung dose and PTV (cm [3]) were
evaluated on the treatment planning workstation.
Diagnosis of OP after SABR
The criteria for the diagnosis of OP after SABR were
defined by reference to previous criteria in breast cancer
studies: [4,6-10] 1) mixture of patchy and ground-glass
opacity, 2) general and/or respiratory symptoms lasting
for at least 2 weeks, 3) radiographic lesion in the lung
volume receiving less than 0.5 Gy, and 4) no evidence of
a specific cause. Most patients in this study were elderly
or had severe comorbid disease. Thus, biopsy could not
be included in these criteria in accordance with the pre-
vious breast cancer studies. The diagnosis was deter-
mined by two physicians (T. M. and A. M.) using the 2-
item questionnaire.
Follow-up studies
Patients were followed at 1- to 2-month intervals after
SABR. Physical examinations, chest radiographs or CT,
and laboratory tests were routinely performed at each
visit. Toxicity was evaluated using Common Termin-
ology Criteria for Adverse Events Version 4. The follow-
up period after SABR ranged from 2 to 85 months
(median, 26 months).
Statistical analyses
The primary endpoint of the study was the incidence of
OP. The time was measured from the date of starting
SABR. First, the cumulative incidence of OP was calcu-
lated by accounting for death or other thoracic irradi-
ation as competing risks [20,21]. To select variables used
in the multivariate analysis, the OP incidence was com-
pared with the Gray test for equality among levels of
covariates: age, sex, site, stage, dose, chemo, rheumatoid
arthritis, PTV (cm [3]), V20 Gy and mean lung dose
[22]. Variables for which p-value was < 0.20 in the Gray
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Age (years) Median 76
(Range 16 - 89)
Planning target volume (cm3) 52.7 ± 29.1**
Mean lung dose (Gy) 4.5 ± 1.8*
V20 Gy† (%) 6.7 ± 3.1*
*This patient could not complete the planned protocol of 48 Gy in 4 fractions.
** Mean ± standard deviation.







Figure 1 Five clinical states and transitions in the multi-state
model. The multi-state model was developed with five clinical states:
the index SABR, RP, OP, death and other thoracic irradiation. Each
arrow denotes the transition between two clinical states. A transition to
RP (gray arrow) was considered as an intermediate event.
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using the semiparametric proportional hazards model of
Fine and Gray [20,23]. The subdistributional hazard ratio
(HR) for a categorical covariate was the ratio to subdis-
tribution hazards for the actual group with respect to
the baseline, with all other covariates being equal
[20,23].
Second, to investigate the impact of the RP incidence
as a time-dependent covariate, the multi-state model
was developed by five clinical states (Figure 1) [24]. The
transitions from SABR to either OP incidence, death, or
other thoracic irradiation are modeled by a competing
risk model. Thus, this multi-state model generalizes the
competing risk model by including an intermediate
event of RP. We assumed that two transitions (Figure 1,
black arrows and white arrows) had common baseline
hazards, respectively. We introduced a time-dependent
covariate that indicated whether or not RP has already
occurred. For a transition from SABR to OP, the value of
this covariate equals zero, while for a transition from RP
to OP, the value equals one. In this analysis, we alsoincluded variables used in the Fine and Gray analysis. A
Kappa agreement score was calculated to evaluate agree-
ment of two physicians.
Proportional hazard assumptions for all variables
included in the univariate and multivariate models were
checked by inspection of the Schoenfeld’s residuals. All
statistical tests were two-sided. These analyses were
implemented in the R package vdc, cmprsk [20,21]or
package mstate [25]. All analyses were performed in R
version 2.13.0 for Windows [26].Results
Clinical courses of patients with OP after SABR
Nine patients developed OP at 6–16 months after SABR.
The incidences of OP were 4.0% (95% confidence inter-
val: 1.7-7.6%) and 5.2% (2.6-9.3%) at 1 and 2 years, re-
spectively (Figure 2). A Kappa agreement score was 1.0.
Opacity outside radiation ports was observed in 2
patients. However, they were asymptomatic, so we did
not regard them as OP patients.
The clinical features of OP patients are shown in
Table 2. An example of OP is shown in Figure 3. Two of
the nine were nonsmokers. Three had emphysema. No
patient had a history of allergy-related symptoms or
rheumatoid arthritis. All these patients had NSCLC
(T1N0M0, 4 patients; T2aN0M0, 5 patients) and were
treated with SABR alone. The median PTV (cm [3]),
V20Gy and mean lung dose were 74.3 cm [3] (range:
42.6-102.1), 7.5% (3.6-9.7%) and 5.5 Gy (3.6-10.1 Gy), re-
spectively, in these patients. Eight of the 9 patients had
experienced symptomatic RP around the tumor within 3
to 9 months after SABR. OP in the opposite lung and
outside ports appeared 2 to 7 months after the RP. Opa-
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Figure 2 The incidence of OP after SABR. CI denotes confidence
interval.
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negative. All OP patients presented with dyspnea (Grade
2 in 4 patients and Grade 3 in 5). Of the 9 patients, 5
had Grade 3 general fatigue, 5 had fever (≥ 37.5
degrees Celsius) and/or persistent cough, 3 had sputum
and 1 had chest pain. C-reactive protein (CRP) elevation
(≥ 5.0 IU/ml) was observed in 6 patients. KL-6 elevation
(≥ 500 U/ml) was observed in 4 of the 9 patients. Eleva-
tion of white blood cell count (> 10,000/μl) was observed
in only 2 patients. Prednisone (0.5-1 mg/kg) was admi-
nistered to 5 of the 9 patients and their symptoms
and pulmonary infiltrates were improved within 1 to
4 weeks. Prednisone treatment was tapered over 4 to
8 weeks. Antibiotics were administered to 2 patients
without steroids and 2 patients did not receive any
treatment at all. In these cases, the chest radiograph
findings and symptoms improved gradually within 4
to 16 weeks.Table 2 Clinical characteristics of OP patients
No. Age Sex Dose
(Gy/4 fr*)
Toxicity grade (CTCAE v
Dyspnea Fever
1 62 M 52 2
2 80 M 48 2
3 79 M 48 3 1
4 71 F 52 2 1
5 76 M 52 2
6 82 M 52 3 2
7 83 M 52 3 2
8 79 M 50 3 2
9 83 F 50 3
*fr = fractions. **PSL = Prednisone. ††Abx = antibiotics.
† Normal range for KL-6 is ≤ 500 U/ml in the institutions.
CRP and KL-6 data represent the maximum level during the initial OP course. RelapRelapse of OP occurred in 4 patients (Table 2, patient
number 6–9). They received treatment similar to that
used for first OP. One patient needed intubation for
Grade IV dyspnea. One and two episodes of relapse oc-
curred in 2 patients each. One patient suffered first re-
lapse during prednisone tapering. Increasing the
prednisone dose was effective in these patients. At latest
follow-up, none of the 4 patients had clinical symptoms,
although 3 of them were still receiving prednisone at a
dose of 5 mg, and chest roentgenograms revealed small
residual opacities and linear densities in all patients.Multivariate analyses of factors associated with OP after
SABR
In the Gray test, risk factors with a p-value < 0.20 were
PTV (cm [3]) (p= 0.039) and dose (p= 0.19). In the Fine
and Gray analysis, no factor showed statistical signifi-
cance (Table 3). We then investigated the impact of the
RP incidence using a multi-state model (Figure 1). In
this analysis, we also included variables used in the Fine
and Gray analysis. This analysis showed that only prior
symptomatic RP was significantly associated with OP
after SABR (HR: 61.7: 95% confidence interval: 4.1-
928.1, p= 0.0028) (Figure 4).Discussion
We have described the clinical features of OP after
SABR. They were quite similar to those of OP after post-
operative irradiation for breast cancer and clearly dif-
fered from those of RP [4,6-10,27,28]. To the best of our
knowledge, this report represents the first cohort study
on OP after SABR. This study suggests some clinical
implications for SABR. First, OP after SABR occurred in
9 out of 189 (4.8%) in the present study, while previous
reports described OP incidences after postoperative ir-








2 22.7 558 PSL** + Abx††
2 4.0 299 Abx
2 1.1 414 PSL
3 21.0 653 PSL + Abx
3 10.6 231 Abx
3 5.8 531 PSL + Abx
3 5.9 314 PSL + Abx
se of OP occurred in patients No. 6-9.
Figure 3 Chest CT, radiograph and dose distribution of SABR of an 82-year-old patient. Blue represents areas receiving more than 0.5 Gy
(Figure 3 a, b). The patient presented with RP around the tumor 8 months after SABR (Figure 3 c, d arrow). OP occurred 3 months after RP
resolution (Figure 3 e, f arrow head). Opacity around the tumor did not increase significantly (Figure 3 e, f, arrow). After administration of 5 mg
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and this may be related to the relatively large volume of
the lung irradiated at SABR as compared with postopera-
tive irradiation for breast cancer. The symptoms were
sometimes severe, compared to those of patients devel-
oping OP after postoperative irradiation for breast cancer
[8]. Secondly, most OP occurred a few months after RP
in this study. A very strong association between prior RP
history and OP was also shown statistically. All OP devel-
oped within 16 months after SABR. Thus, when a patient
after SABR presents with unusual pneumonia, OP should
be considered in the differential diagnosis. Patients after
SABR should be carefully followed up for at least 2 years,
especially when RP is symptomatic. Finally, the clinical
features of OP after radiation could differ from those ofTable 3 Fine and Gray regression analysis
Patient number HR (95% CI) p-value
Total (with OP)
Dose (Gy/fractions) 0.4
48/4 97 (2) 1
50/4 26 (2) 3.21 (0.47 -21.86)
52/4 and other 66 (5) 2.56 (0.57 -11.53)
PTV (cm3) 0.4
4.5 -44.2 93 (1) 1
44.2 -71.6 48 (3) 5.98 (0.65 -54.7)
71.6 -192 48 (5) 7.46 (0.84 -66.3)RP. Patchy consolidation and ground-glass opacity are
frequently observed in both of these diseases. [6-10] In
addition, bilateral RP outside the radiation port is occa-
sionally observed. However, RP in the contra-lateral lung
is less marked than that around the tumor [6-10]. In OP
patients, opacity appeared dominantly outside radiation
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Figure 4 Incidence of OP after SABR in patients with (+) and
without (−) prior symptomatic RP in multi-state model. CI
denotes confidence interval.
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around the tumor was not observed. Future studies on
SABR would prove OP after SABR as a complication sep-
arate from RP.
The mechanism of OP after radiation has not been
understood well. This study offers some clues and
insights. Most OP patients had a history of prior RP
around the tumor in this study. This result would indicate
that radiation injury plays an important role in the devel-
opment of OP after SABR. Previous studies reported that
radiation can directly induce Fas expression in cells and
activate inflammatory cells expressing Fas-ligand (macro-
phages and T cells) [29-31]. Martin et al. [32]. reported
that unilateral thoracic irradiation induced elevation of
lymphocytes in bilateral lungs. In OP model mice, neo-
natal thymectomy inhibited the development of OP [33].
Mice with blockage of the Fas/Fas-ligand apoptotic path-
way could not develop OP [34]. Thus, OP development
may require the T-cell and Fas/Fas-ligand pathways,
which can be activated by radiation in OP after SABR.
Interestingly, OP after SABR occurred outside the lung
volume receiving less than 0.5 Gy. Although a radiation
dose less than 0.5 Gy is generally too low to induce cell
death directly, it is sufficient to induce a bystander effect
[35,36]. The bystander effect is defined as a non-targeted
phenomenon induced by low dose radiation, and
includes mutations, genetic instability, formation of
micronuclei and apoptosis [35]. The mechanisms involve
inflammatory cells and biochemical and molecular sig-
nals, for example, tumor necrosis factor-alpha, nitric
oxide and superoxide. Tumor necrosis factor-alpha
enhances Fas mediated apoptosis in lung epithelial cells
[37]. In this study, no significant relationships between
OP and radiation intensity, such as prescribed doses
were observed. This result is consistent with previous
reports on bystander effects; in most studies, the magni-
tude had no simple relationship with dose [35,38]. Satur-
ation of responses may occur due to a limit of how
much signal can be produced by the irradiated cells.
Therefore, if an interaction between the bystander effect
and activated T-cells and Fas/Fas-ligands by direct radi-
ation plays an important role in OP after SABR, a dose
response model may not apply to OP after radiation.
This study had some limitations. First, the definition
of OP in this study was determined by the clinical
course and radiological findings with reference to previ-
ous criteria in breast cancer studies. Neither biopsy nor
bronchoalveolar lavage could be performed in this study,
because the OP patients were too frail or too old to
undergo these invasive examinations, or refused them.
Generally, characteristics of OP on CT images are well
correlated with histological characteristics [1,3,39]. OP is
characterized by mixture of patchy and ground-glass
opacity in subpleural or peribronchial areas on CT.These findings correspond to the histological findings of
mild inflammation and polypoid plugs of loose organiz-
ing connective tissue with or without endobronchiolar
intraluminal polyps. The architecture of the lung is pre-
served. Although most of the differential diagnoses like
other malignancies and pulmonary infectious diseases
could be excluded in the appropriate clinical context, it
is possible that the true incidence of OP was overesti-
mated [3,39]. Secondly, we could not completely exclude
other causes, especially lung cancer. Malignancy some-
times induces OP [3,40]. Thus, we started a multi-
cohort study to evaluate OP incidences between a sur-
gery group and an SABR group.
In conclusion, this report is the first cohort study to de-
scribe the incidence and characteristics of OP after SABR.
Prior symptomatic RP was strongly associated with OP.
The symptoms were sometimes severe and corticosteroids
were effective. Patients after SABR should be carefully fol-
lowed, especially when RP is symptomatic. When patients
after SABR present with unusual pneumonia, this disease
should be considered in the differential diagnosis.
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